Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
AbstractPurpose of ReviewThis review discusses whether patients ’ genotype affects the efficacy of PCSK9 inhibitors in treating familial hypercholesterolemia and how this might influence clinical management.Recent FindingsCurrently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for compound heterozygous and homozygous familial hypercholesterolemia (FH). However, it remains to be seen whether the comparable therapeutic effect in lowering LDL-C level also leads to a comparable degree of cardiovascular...
Source: Cardiovascular Drugs and Therapy - August 23, 2023 Category: Cardiology Source Type: research
Effect of Beta-Blocker on Long-Term Major Cardiovascular Events in High Atherosclerotic Risk Population
ConclusionIn patients with high atherosclerotic cardiovascular risk, taking beta-blockers had a higher risk of 3P-MACEs. Care should be taken when prescribing beta-blockers to patients without a clear indication.Trial registrationTCTR20130520001 registered in Thai Clinical Trials Registry (TCTR)https://www.thaiclinicaltrials.org/, date of registration 20 May 2013. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 18, 2023 Category: Cardiology Source Type: research
High BMI: Another Barrier to Rapid Platelet Inhibition After STEMI PCI
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 18, 2023 Category: Cardiology Source Type: research
Effect of Beta-Blocker on Long-Term Major Cardiovascular Events in High Atherosclerotic Risk Population
ConclusionIn patients with high atherosclerotic cardiovascular risk, taking beta-blockers had a higher risk of 3P-MACEs. Care should be taken when prescribing beta-blockers to patients without a clear indication.Trial registrationTCTR20130520001 registered in Thai Clinical Trials Registry (TCTR)https://www.thaiclinicaltrials.org/, date of registration 20 May 2013. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 18, 2023 Category: Cardiology Source Type: research
High BMI: Another Barrier to Rapid Platelet Inhibition After STEMI PCI
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 18, 2023 Category: Cardiology Source Type: research
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
ConclusionSemaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 14, 2023 Category: Cardiology Source Type: research
Antiphospholipid Syndrome: State of the Art of Clinical Management
AbstractAntiphospholipid syndrome (APS) is a systemic autoimmune disorder clinically characterized by recurrent arterial and venous thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies. Currently, treatment is mainly focused on anticoagulation, but therapies targeting mechanisms involved in APS autoimmune pathogenesis could play an important role in specific settings. An evidence-based therapeutic approach is limited by the broad clinical spectrum of the syndrome and the nature of a “rare disease” that makes it difficult to carry out well-designed prospective studies. Vitamin K antagonis...
Source: Cardiovascular Drugs and Therapy - August 12, 2023 Category: Cardiology Source Type: research
Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China
ConclusionsARB administration was significantly associated with a lower risk of all-cause mortality in patients with COVID-19 and CVDs.Trial registrationClinicalTrials.gov NCT05615792.https://www.clinicaltrials.gov/ct2/show/NCT05615792 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 11, 2023 Category: Cardiology Source Type: research
Direct Oral Anticoagulants: Navigating Through Clinical Challenges
ConclusionThe purpose of this study is to provide guidance for healthcare professionals for making proper decisions when confronted with clinical challenges. Nevertheless, further research is required to establish DOAC superiority in complicated cases, where there is clinical uncertainty. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 8, 2023 Category: Cardiology Source Type: research
Iron Status Screening in Individuals with Heart Failure Before Initiating Sodium-Glucose Cotransporter 2 Inhibitor Therapy: Is It Necessary?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - August 7, 2023 Category: Cardiology Source Type: research
